[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:macular-degeneration":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,44,74,90,159,182,207,239,266,291,315,345,381,404,433,459,483,503,554,582,601,620],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100576014","a-study-to-learn-how-avacincaptad-pegol-izervay-is-used-in-clinical-practice-in-people-who-have-geographic-atrophy-100576014",false,"NCT06779773","A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy","A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP\u002FIZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration","Inclusion Criteria:\n\n* Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes\n* Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment\n* Patient willingness to complete the patient reported outcome (PRO).\n\nExclusion Criteria:\n\n* Patients who have any contraindication or are not eligible for treatment with ACP, including the following:\n\n  * Active ocular or peri-ocular infection in either eye\n  * Active, suspected intraocular inflammation in either eye\n  * Hypersensitive to ACP or to any ingredient in the formulation\n* Patients currently participating in an investigational program with interventions outside of routine clinical practice.\n* Patients who have received ACP in the eye being considered for enrollment. Note: Patients who have received or are receiving ACP in the fellow eye at baseline are eligible to be included in the study.\n* Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.","ALL",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.\n\nAvacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.\n\nThis study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).\n\nPeople that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.",[23,24],"Geographic Atrophy","Macular Degeneration",[26,27,28,29,30],"Avacincaptad Pegol","IZERVAY™","Treatment patterns","Safety","Functional Outcomes","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2025-01-22",{"date":39,"type":19},"2030-10-31",{"name":41,"class":42},"Astellas Pharma Global Development, Inc.","INDUSTRY",65,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100631122","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-003-100631122","NCT07496567","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-003)","A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2\u002F3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201\u002FMK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)","TORRONTES","The main inclusion criteria include but are not limited to the following:\n\n* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)\n* The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment\n\nThe main exclusion criteria include but are not limited to the following\n\n* Has uncontrolled blood pressure at screening\n* History of any prior macular laser photocoagulation in the study eye\n* History of uveitis in either eye\n* History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study\n* Has uncontrolled glaucoma in the study eye\n* Active retinal disease other than the condition under investigation in the study eye\n* Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye","50 Years",{"count":54,"type":19},960,"INTERVENTIONAL",[57,58],"PHASE2","PHASE3","Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).\n\nAvailable standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.\n\nThe goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.",[24,61,62,63],"Age-Related Macular Degeneration","Choroidal Neovascularization","Wet Macular Degeneration","2026-06-27",{"date":66,"type":35},"2026-06-30",{"date":68,"type":35},"2026-04-15",{"date":70,"type":19},"2028-07-31",{"name":72,"class":42},"EyeBiotech Ltd.",48,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":49,"acronym":79,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":81,"briefSummary":59,"conditions":82,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100626791","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-002-100626791","NCT07440225","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-002)","MALBEC",{"count":54,"type":19},[57,58],[24,61,62,63],{"date":66,"type":35},{"date":85,"type":35},"2026-03-27",{"date":87,"type":19},"2028-06-30",{"name":72,"class":42},71,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":55,"phases":100,"briefSummary":102,"conditions":103,"keywords":120,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":158},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.","18 Years",{"count":18,"type":19},[101],"NA","This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[104,61,105,106,107,108,109,110,111,112,113,114,115,116,117,118,24,119],"Retinal Disease","Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Glaucoma","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision Loss Partial","Vision, Low","Retinopathy","Maculopathy","Retina Atrophy",[121,122,123,124,125,126,127,128,129,104,24,130,131,23,132,63,133,134,135,136,105,106,137,138,139,118,110,109,107,140,141,142,143,144,145,146,147,148,112,113,149,119],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Dry Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss","2026-06-24",{"date":152,"type":35},"2026-06-29",{"date":154,"type":35},"2016-01",{"date":70,"type":19},{"name":157,"class":42},"MD Stem Cells",4,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":55,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100564897","phase-2-a-long-term-extension-study-of-jnj-81201887-aavcagscd59-parent-studies-in-participants-with-geographic-atrophy-ga-secondary-to-age-related-macular-degeneration-amd-100564897","NCT06635148","A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies","Inclusion Criteria:\n\n* Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)\n* Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study\n* Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and\u002For legally designated representative depending on national\u002Flocal regulations\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this LTE study","60 Years",{"count":168,"type":19},274,[57],"The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.",[23,24],"2026-06-04",{"date":174,"type":35},"2026-06-05",{"date":176,"type":35},"2024-09-19",{"date":178,"type":19},"2030-07-16",{"name":180,"class":42},"Janssen Research & Development, LLC",104,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":188,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":55,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":206},"100637773","vision-rehabilitation-training-with-multimodal-feedback-in-central-vision-loss-100637773","NCT07577219","Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss","Inclusion Criteria:\n\nBilateral central scotomas confirmed via computerized tangent screen Visual acuity between 20\u002F60 and 20\u002F200 (0.5 - 1.00 logMAR) in either eye Stable central vision loss (no change in visual acuity \\>0.2 logMAR in past 6 months) Age 14 years or older, with diagnosis of macular disease Normal cognitive function (Mini-Mental State Examination score ≥24) Ability to provide informed consent and complete study visits No major hearing loss Fluent in English\n\nExclusion Criteria:\n\nUnstable ocular disease (e.g., ongoing treatments and\u002For injections) Peripheral vision loss of less than 40 degrees Conditions affecting oculomotor control independent of CVL","14 Years",{"count":190,"type":19},12,[101],"Central vision loss from macular degeneration creates blind spots that impair reading, face recognition, and navigation. Individuals must learn to use peripheral vision, requiring retraining of eye movements. Our preliminary research using high-speed eye tracking demonstrated that people with larger scotomas have impaired eye movement control, and that single-session visual feedback training showed limited immediate benefit, though combining feedback types showed promise.\n\nThis study will evaluate whether extended binocular training (5 weekly sessions) with multimodal feedback improves eye movement control in 8-15 participants with bilateral central vision loss. Unlike conventional monocular rehabilitation systems, our approach trains both eyes simultaneously using real-time visual and auditory feedback during saccadic and smooth pursuit tasks. Participants will receive gaze-contingent scotoma awareness feedback, preferred retinal locus feedback, and auditory cues while performing eye tracking exercises.\n\nPrimary outcomes include saccadic accuracy (latency, landing error, amplitude) and smooth pursuit parameters (gain, tracking accuracy). Secondary outcomes include contrast sensitivity and self-reported visual function. Success could establish an evidence base for accessible home-based training using virtual reality technology, potentially benefiting millions with macular degeneration.",[194,195,24],"Low Vision","Central Visual Impairment","2026-05-05",{"date":198,"type":35},"2026-05-11",{"date":200,"type":35},"2026-01-31",{"date":202,"type":19},"2026-12-01",{"name":204,"class":205},"New England College of Optometry","OTHER",1,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":215,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100631218","artificial-intelligence-assisted-diagnosis-in-ophthalmology-100631218","NCT07497815","Artificial Intelligence-assisted Diagnosis in Ophthalmology","Development and Validation of an Artificial Intelligence-assisted Diagnostic System for Ophthalmic Pathologies","AI-OPHTH-CR","Inclusion Criteria:\n\n* Image corresponds to patient ≥18 years of age at time of capture\n* Image modality is one of: fundus photography, posterior segment OCT, anterior segment photography, automated perimetry, or video-OCT\n* Image quality sufficient for diagnostic interpretation (adequate resolution, focus, illumination, complete visualization of anatomical area of interest, no major artifacts)\n* Minimum clinical data available (age or age group, sex, and diagnosis or clinical indication)\n* Image captured during routine clinical care (not specifically for research)\n* No patient objection to use of medical data for research (when applicable per center policy)\n\nExclusion Criteria:\n\nCLINICAL:\n\n* Images from eyes with recent intraocular surgery (\\\u003C3 months)\n* Images from eyes with severe ocular trauma distorting anatomy\n* Images from patients with rare or unique ocular pathologies not allowing generalization\n* Images post-recent laser treatment where acute changes may confuse analysis\n\nTECHNICAL:\n\n* Severely degraded image quality (extreme blur, severe under\u002Foverexposure, major artifacts preventing interpretation)\n* Duplicate images of same eye on same date\n* Images with missing or clearly erroneous metadata\n* Images in non-standard or corrupted formats that cannot be processed\n\nSex\u002FGender: All Minimum Age: 18 Years Maximum Age: No limit Accepts Healthy Volunteers: Yes (images of healthy eyes without pathology are included as controls)",true,{"count":217,"type":19},15000,"This is a retrospective, multicenter, observational study designed to develop and validate an artificial intelligence (AI) system capable of detecting and classifying major ophthalmic diseases (glaucoma, cataract, diabetic retinopathy, and other retinal pathologies) in the Costa Rican population. The study will use approximately 15,000 existing medical images from digital archives of two ophthalmic centers in Costa Rica, without active participant recruitment or capture of new images.\n\nThe primary motivation is that AI systems developed in other countries (primarily Asian, European, or North American populations) do not necessarily perform with the same accuracy when applied to Latin American populations. This study seeks to establish a precedent for the importance of locally validating any medical AI technology before clinical implementation.",[24,220,111,221,222],"Diabetic Retinopathy (DR)","Keratoconus","Cataract",[224,225,226,227],"artificial inteligence","ophthalmology","imaging","bias","NOT_YET_RECRUITING","2026-03-26",{"date":231,"type":35},"2026-04-01",{"date":233,"type":19},"2026-05-01",{"date":235,"type":19},"2029-05-01",{"name":237,"class":42},"Marisse Masis-Solano",2,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":55,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":206},"100474148","factors-in-learning-and-plasticity-macular-degeneration-100474148","NCT05454124","Factors in Learning And Plasticity: Macular Degeneration","Characterization of Multiple Factors in Training and Plasticity in Central Vision Loss: Macular Degeneration","FLAP","Inclusion Criteria:\n\n* Aged 18-89\n* Severely impaired vision in both eyes (20\u002F100 or worse)\n* diagnosis of Macular Degeneration by an Ophthalmologist\n* Light sensitivity in the macular retina that is at least 10 dB units worse than in peripheral regions, as demonstrated by a scanning laser ophthalmoscope (MAIA)\n* Medical record review indicating this level of disease severity has been present for at least 2 years\n* Reside within 50 miles of study site\n\nExclusion Criteria:\n\n* Pacemaker or any ferromagnetic metal implanted in their body\n* Metal of any type implanted in their head (limited dental work is acceptable)\n* Claustrophobia\n* Being hearing-impaired\n* Weight over 300 pounds\n* Maximum body girth over 60 inches\n* Previous serious head injury\n* Presence of hallucinations or delusions\n* Excessive old, or colorful tattoos, especially near the head\n* Pregnancy\n* Braces\u002Fpermanent retainer","89 Years",{"count":249,"type":19},60,[101],"A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the NIMH RDOC framework and studies in an aging population are consistent with the mission of the NIA.",[195,24],[254,255,256],"plasticity","central vision loss","perceptual learning","2026-02-04",{"date":259,"type":35},"2026-02-09",{"date":261,"type":35},"2022-11-01",{"date":263,"type":19},"2026-11",{"name":265,"class":205},"University of Alabama at Birmingham",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":215,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":55,"phases":275,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":206},"100363123","early-phase-1-feasibility-and-safety-of-mb-102-in-ocular-angiography-as-compared-to-fluorescein-sodium-100363123","NCT04008121","Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium","A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium","Inclusion Criteria:\n\n* Age \\> 18 years - male or female\n\n  1. Eligible female non-pregnant participants who are either not of child-bearing potential or willing to utilize adequate contraception during the trial\n  2. Males must be willing to practice abstinence or utilize adequate contraception from MB-102 dosing day to at least 7 days post dose\n* Participants willing to comply with study requirements\n* Participants who have signed an informed consent form\n\nAt least 5 participants will have a current history of retinal or choroidal vascular diseases.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to utilize adequate contraception\n* Participation in another interventional trial within 30 days of treatment or concurrently enrolled in any other medical research study which could impact the results of the study\n* History of drug or alcohol abuse within the past year\n* History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 and fluorescein sodium or other related products (intolerance to a drug is not considered a drug allergy).\n* Prior history of seizures\n* Current visually significant cataracts or other ophthalmic conditions that would limit appropriate collection of fundus photographs\n* Site personnel immediately associated with the study or their immediate family members\n* Unable to tolerate ophthalmologic imaging\n* Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial (e.g. unstable medical condition including cardiovascular disease, or other conditions considered clinically significant or unstable by the Principal Investigator)\n* Prior enrollment and dosing in this study",{"count":274,"type":19},10,[276],"EARLY_PHASE1","The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.",[117,279,280,24],"Retinal Vein Occlusion","Diabetic Retinopathy",[282],"Fluorescein angiography","2026-02-02",{"date":257,"type":35},{"date":286,"type":35},"2025-11-06",{"date":288,"type":19},"2026-12",{"name":290,"class":42},"MediBeacon",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":55,"phases":301,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":206},"100621181","phase-4-evaluate-the-efficacy-of-faricimab-in-patients-with-neovascular-age-related-macular-degeneration-100621181","NCT07367282","Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration","A Phase IV, Prospective, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy of Faricimab and Biomarker Assessment in Patients With Neovascular Age-related Macular Degeneration","nAMD","Inclusion Criteria:\n\n1. Individuals who voluntarily agree to participate in this clinical study and provide written informed consent\n2. Male or female adults aged 50 years or older at the time of consent\n3. Individuals who, in the opinion of the investigator, are capable of complying with the requirements of the study protocol\n\nOcular Conditions\n\n1. Individuals with a BCVA equivalent of ETDRS 24 letters or more, as measured at the time of screening.\n2. Confirmed diagnosis, by the investigator, of active nAMD based on sufficiently clear ocular media and adequate pupillary dilation allowing acquisition of good quality retinal images for confirmation.\n3. Treatment naïve patients\n4. For PCV patients, presence of active polypoidal lesions in the macula as shown by Indocyanine green angiography (ICGA) AND presence of serosanguinous maculopathy\n5. For PCV patients, greatest liner dimension (GLD) of the total lesion area \\\u003C5400 μm as delineated by ICGA.\n\nExclusion Criteria:\n\n1. Any major illness or major surgical procedure within 1 month before screening.\n2. Any condition that, in the opinion of the investigator, constitutes a contraindication to the use of faricimab, may affect interpretation of study results, or places the participant at high risk for treatment-related complications, based on medical history, non-diabetic metabolic abnormalities, physical examination findings, or past\u002Fcurrent clinical laboratory results.\n3. History of active cancer within 12 months prior to screening, except for adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer, or prostate cancer with a Gleason score ≤6 (Grade Group 1) and stable PSA levels for \\>12 months.\n4. Uncontrolled blood pressure, defined as systolic \\>180 mmHg and\u002For diastolic \\>100 mmHg while at rest at baseline. A repeat reading within the screening window may be taken to confirm eligibility.\n5. Immune system abnormalities that may affect inflammatory biomarkers in aqueous humor (AH).\n6. History of severe allergic or anaphylactic reaction to biologic agents, or known hypersensitivity to any component of the faricimab injection, study-related procedures (including fluorescein and indocyanine green dyes), dilating drops, or any anesthetic\u002Fantimicrobial eye drops used during the study.\n7. Systemic treatment for suspected or active systemic infection at screening. Ongoing prophylactic antibiotic use may be acceptable at the investigator's discretion.\n8. Use of systemic medications known to have toxic effects on the lens, retina, or optic nerve within 6 months prior to screening or within 5 drug half-lives (whichever is longer), or expected future use of such medications.\n9. Receipt of systemic immunomodulatory therapy or immunosuppressive agents within 6 months prior to screening or within 5 drug half-lives (whichever is longer).\n10. Participation in another clinical study involving an investigational drug, investigational device, or other medical research within 3 months prior to screening, or concurrent participation in such a study.\n11. Pregnant or breastfeeding women.\n12. Women of childbearing potential planning to become pregnant during the study or within 3 months after the last dose of study treatment, or unwilling to use highly effective contraception methods\\* throughout the study period and for 3 months following the last dose.\n\nOcular Conditions\n\n1. Any ocular condition in the study eye that may interfere with the assessment of visual acuity, safety evaluation, or fundus imaging (e.g., advanced cataract).\n2. Any current ocular disease in the study eye that, in the opinion of the investigator, increases the procedural risk of intravitreal injection beyond standard expectations or may interfere with injection, efficacy, or safety evaluations.\n3. Presence of fibrosis or atrophy involving ≥50% of the total lesion area and\u002For the fovea in the study eye, as determined by the investigator.\n4. Presence of retinal pigment epithelial (RPE) tear involving the macula in the study eye.\n5. High myopia with spherical equivalent refractive error \\>6 diopters in the study eye. For participants with a history of refractive or cataract surgery, pre-surgical refractive error must not have exceeded -6 diopters.\n6. Presence of vitreous hemorrhage in the study eye at screening or baseline visits.\n7. History of other macular diseases in the study eye that are unrelated to nAMD but may lead to visual loss or cause intraretinal fluid (IRF) or subretinal fluid (SRF).\n8. History or clinical evidence of proliferative diabetic retinopathy, diabetic macular edema, or other retinal vascular diseases in the study eye, other than AMD.\n9. Any current ocular condition in the study eye (e.g., cataract) that, in the opinion of the investigator, may require medical or surgical intervention during the study period.\n10. History of prior intraocular surgery in the study eye, including but not limited to vitrectomy, glaucoma surgery, corneal transplant, radiation therapy, retinal detachment repair (e.g., scleral buckle or pneumatic retinopexy), trabeculectomy, or other filtration surgeries.\n11. History of prior or ongoing treatment for macular neovascularization (MNV) or vitreomacular interface abnormalities in the study eye, including but not limited to intravitreal therapy (faricimab, other anti-VEGF agents, corticosteroids, tissue plasminogen activator, ocriplasmin, C3F8 gas, air), periocular pharmacological interventions, argon laser photocoagulation, verteporfin photodynamic therapy, diode laser, transpupillary thermotherapy, or ocular surgical procedures.\n12. Presence of glaucoma in the study eye with uncontrolled intraocular pressure ≥25 mmHg despite pharmacological therapy.\n13. Presence of active ocular inflammation or suspected or active ocular or periocular infection in either eye at screening.",{"count":300,"type":19},64,[302],"PHASE4","If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected. If both eyes are eligible, the eye with the worst best-corrected visual acuity (BCVA) at screening will be chosen. However, if the investigator determines that the other eye requires more urgent treatment for clinical reasons, that eye may be selected as the study eye.\n\nAfter screening assessments and evaluation based on inclusion\u002Fexclusion criteria, eligible subjects will be enrolled. Vabysmo® 6 mg (0.05 mL) will be administered via intravitreal injection every 4 weeks (monthly) for a total of 4 doses during the initial loading period. After the loading dose, patients will undergo disease activity assessment based on imaging and visual acuity (VA) outcomes followed by the IP administration at Week 20. The treatment interval will be determined based on disease activity assessed at Week 20, depending on the results, the subsequent administration may be scheduled at Week 28 or Week 32, at the investigator's discretion. Thereafter, the dosing interval may be further adjusted in 4-week increments, either extended or shortened, according to imaging and visual outcomes.\n\nThroughout the clinical study, patients will need to visit the study site at least 10 times, including the screening visit. The number of intravitreal injections administered will be 4 doses during the initial loading period and up to 5 doses during the treat-and-extend (T\\&E) period (Weeks 20, 28, 36, 44, 52). Thus, the total number of injections during the study will range from a minimum of 7 to a maximum of 9 injections.\n\nIf the non-study eye also has nAMD, treatment with a locally approved therapy may be administered outside the scope of this study.",[24],[306],"Neovascular Age-related Macular Degeneration","2026-01-25",{"date":309,"type":35},"2026-01-27",{"date":231,"type":19},{"date":312,"type":19},"2028-12-31",{"name":314,"class":205},"Junyeop Lee",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":55,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":343,"locationsCount":238},"100421022","learning-study-improving-vision-in-adults-with-macular-degeneration-100421022","NCT04762368","Learning Study: Improving Vision in Adults With Macular Degeneration","Improving Vision in Adults With Macular Degeneration, Study 2: The Effect of Concurrent Perceptual Learning and Brain Stimulation","Inclusion Criteria:\n\n1. Diagnosis of AMD (age 60+) or JMD (current age 18+).\n2. Visual acuity (VA); between 6\u002F9-6\u002F96 in the better eye\n3. Best-corrected near visual acuity of 4.0M at 40 cm or better in the better eye\n4. Stable vision in previous 3 months (patient report)\n5. Central vision loss\n\nExclusion Criteria:\n\n1. Diagnosed dementia.\n2. Not fluent in reading English (Waterloo) or Chinese characters (Hong Kong).\n3. Any ocular surgery (including anti-vegF injections) within the duration of the study, except for: A. Chronic and continuous injections for at least 1 year. B. Injections stopped at least 2 months before participation. C. Injections in the untested eye\n4. Ocular pathology other than JMD or AMD that can significantly reduce central vision. Example: mild cataract of grade 2 or below is acceptable\n5. Severe hearing impairment.\n6. Contraindications for brain stimulation",{"count":323,"type":19},30,[101],"The purpose of this study is to test whether a kind of brain stimulation called anodal transcranial direct current stimulation (a-tDCS) can be combined with perceptual learning to improve the ability of people with age-related macular degeneration (AMD) or juvenile macular degeneration (JMD) to read words presented to them on a computer screen better than if perceptual learning alone were used.\n\nIn addition, secondary measures of visual acuity will also be examined to determine whether brain stimulation can allow patients to resolve finer details of an image. The proposed treatment is the application of a-tDCS onto the participant's head, with brain stimulation aimed at Primary Visual Cortex toward the occipital pole, while patients undergo six separate sessions of training. The investigators will test the ability of participants to read words before the start of the training sessions (pre test) and after the completion of all training sessions (post test). This is a between-subjects design, and half of the participants will receive true stimulation, and the other half will receive sham stimulation. The difference between the pre and post tests when receiving active stimulation will be compared to the difference when receiving sham stimulation, because the sham stimulation is not expected to influence reading beyond a placebo. The aim of the study is to examine the potential of concurrent brain stimulation and perceptual learning as an effective treatment for macular degeneration that may be used in conjunction with more traditional eye-based interventions. The investigators hypothesize that the brain stimulation will enable higher performance in the reading task after and secondary measures after perceptual training due to an increase in the cortical excitability of the stimulated brain cells.",[24],[24,328,329,330,331,332,333,334,335,336],"Brain Stimulation","Psychophysics","Reading","tDCS","RSVP","Visual Acuity","Uncrowded Visual Acuity","Crowded Visual Acuity","Contrast Sensitivity","2026-01-21",{"date":339,"type":35},"2026-01-22",{"date":341,"type":35},"2021-02-13",{"date":288,"type":19},{"name":344,"class":205},"University of Waterloo",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":215,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":355,"conditions":356,"keywords":365,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":206},"100599518","natural-history-study-of-inherited-retinal-diseases-100599518","NCT07085533","Natural History Study of Inherited Retinal Diseases","Color Vision Loss Progression in IRD Patients: Retinal Structural Changes Correlations, and a Novel Color Discrimination Test for Extreme Low Vision Patients","MojiLVCDT","Inclusion Criteria:\n\n1. Color Perception and Communication Ability Participants must have the ability to verbally identify or describe colors and test stimuli. This requires adequate cognitive and communicative capacity to understand instructions and respond appropriately during color vision testing.\n2. Diagnosis of Inherited Retinal Dystrophy (IRD Group Only) Participants assigned to the IRD group must have a confirmed clinical diagnosis of an inherited retinal dystrophy\n3. No Evidence of Inherited Retinal Disease (Control Group Only)\n\nParticipants in the control group must have:\n\n* No known history or clinical evidence of inherited retinal degeneration\n* Normal retinal health or only non-retinal ocular conditions not affecting retinal function (e.g., mild cataract, corrected refractive error)\n* Normal or expected-normal color vision\n\nExclusion Criteria:\n\n1. Non retinal causes of color vision loss\n\n   * Optic neuropathies (e.g., optic neuritis, glaucoma related optic nerve damage)\n   * Cortical vision impairments affecting color perception\n   * Any other neurological or optic nerve pathology causing color vision deficiency\n2. Psychological or cognitive conditions affecting color perception or communication\n\n   * Severe developmental delays\n   * Cognitive impairments interfering with ability to comprehend or reliably perform color vision tests\n   * Psychiatric conditions that impair visual interpretation or reliable testing\n3. Prior treatment with potential transient effects on the retina\n\n   * Recent retinal surgery\n   * Recent drug therapy affecting retinal structure or function\n   * Any acute intervention that might confound the correlation analyses due to lack of a stable baseline",{"count":354,"type":19},200,"This prospective, observational investigation seeks to delineate the interplay between chromatic vision deficits and both functional visual outcomes and anatomical retinal biomarkers in individuals affected by Inherited Retinal Dystrophies (IRDs). The study will recruit approximately 200 subjects, encompassing a heterogeneous population of IRD patients-spanning a range of genotypes and clinical severities-as well as control participants devoid of retinal pathology. All enrolled individuals will undergo a standardized battery of evaluations, including quantitative color vision assessment, best-corrected visual acuity (BCVA) determination, and advanced multimodal retinal imaging.\n\nThe principal aim is to characterize the relationship between impairments in color discrimination and morphologic disruptions within the outer retinal layers, with particular emphasis on the continuity and reflectivity of the ellipsoid zone (EZ)-historically referred to as the inner segment\u002Fouter segment (IS\u002FOS) junction-assessed through spectral-domain optical coherence tomography (SD-OCT). Further, the study will explore associations between chromatic perceptual deficits and underlying genetic mutations, mutation patterns specific to IRD subtypes, and the influence of patient age on the severity and progression of color vision loss.\n\nA key secondary objective is the clinical appraisal and validation of a novel diagnostic modality, the Moji Low-Vision Color Discrimination Test (Moji Test), which is specifically engineered to quantify residual color perception in individuals with advanced central visual impairment. The test's discriminatory capacity will be benchmarked against established color vision testing paradigms to assess its reliability, clinical sensitivity, and suitability for implementation in populations with severe visual acuity reduction.\n\nBy incorporating a genetically and phenotypically diverse IRD cohort, the study is designed to enable granular, stratified analyses that will refine the understanding of structural-functional correlations in hereditary retinal disease. The inclusion of a control group with preserved retinal architecture and normal color vision function will provide essential normative baselines for comparative evaluation and statistical inference.",[357,358,359,24,360,361,333,362,363,364],"Retinal Dystrophies","Color Vision Defects","Vision Disorders","Achromatopsia","Optical Coherence Tomography (OCT)","Genotype","Mutation","Phenotype",[366,367,368,369,370,371],"observational","IRD","ultra low vision","inherited retinal disease","color vision","color test","2025-12-03",{"date":374,"type":35},"2025-12-10",{"date":376,"type":35},"2025-07-20",{"date":378,"type":19},"2027-09-28",{"name":380,"class":42},"Zhongmou Therapeutics",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":387,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":55,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":206},"100609618","remapping-text-in-sentence-and-word-tasks-to-aid-reading-with-central-vision-loss-100609618","NCT07216924","Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss","Inclusion Criteria:\n\n* Dense bilateral scotomas of at least 2 deg diameter in each eye covering the fovea\n* Bivariate contour ellipse area (BCEA) of less than 10\\^2 is obtained in a simple fixation task\n\nExclusion Criteria:\n\n* Neovascular AMD\n* Any history of visual disorders other than that causing the central vision loss.","16 Years",{"count":389,"type":19},100,[101],"Reading performance in patients with Central Vision Loss will be measured with and without missing text being remapped to different parts of the visual field in a variety of different reading tasks.",[24,195],[330,394],"Central Field Loss","2025-10-13",{"date":397,"type":35},"2025-10-15",{"date":399,"type":19},"2026-06",{"date":401,"type":19},"2032-05",{"name":403,"class":205},"University of Minnesota",{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":55,"phases":413,"briefSummary":414,"conditions":415,"keywords":419,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":206},"100539559","phase-3-a-efficacy-and-safety-study-of-ranibizumab-10mgml-injection-incepta-in-patients-with-diabetic-macular-edema-100539559","NCT06305416","A Efficacy and Safety Study of Ranibizumab 10mg\u002Fml Injection (Incepta) in Patients With Diabetic Macular Edema","Randomized, Double-blind, Parallel, Active Controlled Study to Compare Efficacy & Safety Between Ranibizumab 10mg\u002Fml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection","Inclusion Criteria:\n\n1. Ages Eligible for Study: ≥ 18 Years\n2. Ability to provide written informed consent and comply with study assessments for the full duration of the study\n3. Diagnosis of diabetes mellitus (type 1 or 2). Any one of the following will be considered to be sufficient evidence that diabetes is present: Laboratory reports that prove DM of patient or current regular use of insulin for treatment of diabetes or current regular use of oral anti-hyperglycemic agent for the treatment of diabetes.\n4. Clinical evidence of retinal thickening due to macular edema involving the center of the macula (can be associated with diabetic retinopathy)\n5. Central diabetic macular edema present on clinical examination and OCT testing with central 1mm sub field thickness greater than 300 microns as measured on -OCT\n6. Visual acuity score greater than or equal to 19 letters (20\u002F400) and less than or equal to 73 letters (20\u002F40) by the ETDRS\u002F Snellen chart visual acuity protocol\n7. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography\n8. Willingness and ability to undertake all scheduled visits and assessments\n\nExclusion Criteria:\n\n1. Prior treatment with any Intravitreal drug, Bevacizumab, verteporfin or photodynamic therapy (except for extra foveal laser photocoagulation) in the study eye within past 3 months before study entry\n2. Laser photocoagulation in the study eye within 1 month before study entry\n3. Participation in another ocular investigation or trial simultaneously\n4. Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.\n5. Blood pressure \\> 160\u002F100 mmHg (systolic above 160 or diastolic above 100) and Random Blood Sugar (RBS) ≥ 12 mmol\u002FL and\u002F or HbA1c ≥ 7.5%\n6. Evidence of vitreoretinal interface abnormality and optic nerve disease after ocular exam or OCT that may be contributing to the macular edema\n7. Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the study period or that could contribute to a loss of best corrected visual acuity over the study period (e.g. cataract that might decrease the vision by 3 or more lines, uncontrolled glaucoma, uveitis, previous corneal transplant etc.). The decision regarding exclusion is to be based on the opinion of the investigator.\n8. An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of sub retinal fibrosis or geographic atrophy).\n9. Presence of suspected ocular or periocular infections, another ocular condition that may affect the visual acuity or macular edema during the course of the study (uveitis, Irvine-Gas)\n10. Vitreous hemorrhage preventing visualization of retina\n11. History of vitreous surgery, cataract surgery, YAG capsulotomy in the study eye within last 3 months of enrolment\n12. Visual acuity \\\u003C20\u002F400 in the fellow eye\n13. Known hypersensitivity to Ranibizumab or any of the components of study medication\n14. History of cerebral vascular accident or myocardial infarction within past 3 months.\n15. Employees of Investigational sites, individuals directly involved with the conduct of the study or immediate family members thereof, prisoners, and persons who are legally institutionalized.\n16. Current use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine\u002F hydroxychloroquine, tamoxifen, phenothiazine, vigabatrin and ethambutol, and such medications will not be allowed during the study period.",{"count":412,"type":19},70,[58],"Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma constituents into the surrounding retina and consequently retinal edema. Thickening of the basement membrane and reduction in the number of pericytes are believed to lead to increased permeability and incompetence of the retinal vasculature. This compromise of the blood-retinal barrier leads to the leakage of plasma constituents into the surrounding retina with subsequent retinal edema. Hypoxia produced by this mechanism can also stimulate the production of vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) increases retinal vascular permeability, causes breakdown of the blood-retina barrier and results in retinal edema.\n\nDiabetic macular edema (DME) is the most common cause of visual reduction in patients with Diabetes Mellitus. The prevalence of DME globally is around 6.8 %. Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of blindness worldwide. DME is a complication of diabetic retinopathy that affects the macula, which is located at the center of the retina and responsible for central vision. Bangladesh is the 10th country in the world for the number of adults living with diabetes with some 7.1 million (5.3-12.0). In Bangladesh, it is therefore expected that diabetic secondary complications, like DR, will increase along with the rising trend of diabetes mellitus.\n\nThe use of therapeutic monoclonal antibodies has revolutionized in the treatment of many diseases. In recent years, millions of patients have been successfully treated with these biological agents. Ranibizumab is one such therapeutic monoclonal antibody for intraocular use. Ranibizumab is a humanized, recombinant, immunoglobulin G1 monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A) and thus prevents choroidal neovascularization. The small size of ranibizumab allows for enhanced diffusion into the retina and choroid.",[416,280,417,24,104,418],"Diabetic Macular Edema","Macular Edema","Retinal Degeneration",[420,421,422,129,423],"Ranibizumab","Efficacy","Diabetes","Edema","2025-06-03",{"date":426,"type":35},"2025-06-06",{"date":428,"type":35},"2024-03-30",{"date":430,"type":19},"2025-12",{"name":432,"class":42},"Incepta Pharmaceuticals Ltd",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":55,"phases":442,"briefSummary":444,"conditions":445,"keywords":448,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":238},"100450608","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-naion-100450608","NCT05147701","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Non-arteritic Ischemic Optic Neuropathy","Inclusion Criteria:\n\n* Diagnosis of NAION (non-arteritic ischemic optic neuropathy)\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":441,"type":19},20,[443],"PHASE1","This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy",[446,105,280,24,447,109],"Eye Diseases","Traumatic Optic Neuropathy",[446,105,449,280,24,447,109],"stem cell treatment","2025-04-15",{"date":452,"type":35},"2025-04-17",{"date":454,"type":35},"2022-02-01",{"date":456,"type":19},"2026-01",{"name":458,"class":205},"The Foundation for Orthopaedics and Regenerative Medicine",{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":215,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":206},"100577990","a-prospective-observational-study-to-assess-the-reliability-and-validity-of-the-mlsdt-100577990","NCT06805474","A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT","A Prospective Observational Study to Assess the Reliability and Validity of the Multi-Luminance Shape Discrimination Test (MLSDT) With 9 Objects","Inclusion Criteria:\n\n* Males and females, age ≥ 18 years\n* Able to comprehend and give informed consent.\n* Able to comply with testing and all protocol tests.\n* Eligible for 1 of 3 cohorts listed below:\n\nCohort 1: Normal-Sighted Participants with clinically normal ocular findings and BCVA range 20\u002F16 to \\\u003C20\u002F40 in each eye (ETDRS letter score 71 - 90) Cohort 2: Moderately-Sight Impaired Participants with a BCVA range of 20\u002F40 to \\\u003C20\u002F200 (ETDRS letter score of 36 - 70) and a clinical diagnosis of STGD\u002FGA Cohort 3: Severely-Sight Impaired Participants with a BCVA range of 20\u002F200 to 20\u002F800 (ETDRS letter score of 5 - 35) and a clinical diagnosis of advanced STGD\u002FGA\n\n* Clinical diagnosis of STGD for cohorts 2 and 3\n* Clinical diagnosis for GA (due to AMD) for cohorts 2 and 3\n* Participants who have had anti-VEGF therapy 2 weeks prior to enrollment have to demonstrate 3 months of vision stability and be fluid free on OCT.\n\nExclusion Criteria:\n\n* Concurrent participation in any interventional clinical trial or receipt of an investigational drug within the previous 6 months\n\n  * Presence of any condition other than STGD or GA from AMD on slit lamp exam or dilated ophthalmoscopy that impairs visual acuity or visual fields e.g., corneal opacity, visually significant cataract or visual field loss in glaucoma\n  * No intra-vitreal injection with anti-VEGF two weeks prior to the study\n  * Presence of neurological condition that impairs visual acuity\n  * Individuals who refuse or are incapable of performing the MLSDT of BCVA tests\n  * Individuals with retinal prosthesis (such as ARGUS-II)",{"count":323,"type":19},"The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.",[24,23,106],[470,471,472,473],"Multi-Luminance Shape Discrimination Test","low-vision magnifying aid (eGlasses)","best-corrected visual acuity (BCVA)","Early Treatment Diabetic Retinopathy Study ETDRS","2025-03-18",{"date":476,"type":35},"2025-03-24",{"date":478,"type":35},"2025-01-28",{"date":480,"type":19},"2025-05-27",{"name":482,"class":42},"Nanoscope Therapeutics Inc.",{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":215,"sex":16,"minAge":489,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":206},"100211241","analysis-of-biomarkers-from-patients-with-chorioretinal-diseases-100211241","NCT02026843","Analysis of Biomarkers From Patients With Chorioretinal Diseases","Inclusion Criteria:\n\n* age over 20 years\n* patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity.\n* patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.\n* control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders.\n\nExclusion Criteria:\n\n* under the age of 20 years\n* patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor\n* patients that did not signed the informed consent of the trial\n* patients with intraocular inflammations or infections that requiring any pharmaceutical agent\n* patients with recent ocular trauma","20 Years","80 Years",{"count":389,"type":19},"This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.",[280,24],"2025-03-03",{"date":496,"type":35},"2025-03-06",{"date":498,"type":4},"2012-04",{"date":500,"type":19},"2031-04",{"name":502,"class":205},"Kyungpook National University Hospital",{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":16,"minAge":509,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":512,"conditions":513,"keywords":541,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":206},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":511,"type":19},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,422,531,532,533,24,534,535,536,537,538,539,540],"ALS","Amyotrophic Lateral Sclerosis","Alzheimer Disease","Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Batten Disease","Corticobasal Degeneration","Dementia","Frontotemporal Dementia","Huntington Disease","Lewy Body Disease","Multiple Sclerosis","Multiple System Atrophy","Parkinson Disease","Parkinson's Disease and Parkinsonism","Progressive Supranuclear Palsy","INAD","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Ovarian Cancer","Cervical Cancer","Uterine Cancer","Vaginal Cancer","Vulvar Cancer","PTSD","Post Traumatic Stress Disorder",[514,515,516,519,520,521,522,523,524,525,526,527,542,529,530,422,543,544,24,545,534,535,536,537,538,539,540],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":494,"type":35},{"date":549,"type":35},"2022-11-10",{"date":551,"type":19},"2045-11-10",{"name":553,"class":205},"New York Stem Cell Foundation Research Institute",{"id":555,"slug":556,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":561,"enrollmentInfo":562,"targetDuration":4,"studyType":55,"phases":564,"briefSummary":565,"conditions":566,"keywords":567,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":581},"100546384","phase-1-safety--efficacy-of-eyecyte-rpe-in-patients-with-geographic-atrophy-secondary-to-dry-age-related-macular-degeneration-100546384","NCT06394232","Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.","A Phase 1\u002F2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","Inclusion Criteria:\n\n1. Men and women ≥ 50 years of age at Screening.\n2. Diagnosis of Geographic Atrophy secondary to d-AMD\n3. Have Best Corrected Visual Acuity (BCVA) equal to or less than 20\u002F200 Snellen (ETDRS letter score ≤ 35) in the study eye at screening.\n\n   1. Phase 1 ≤ 20\u002F200 and\n   2. Phase 2a ≥ 20\u002F64 (ETDRS letter score 60) in the study eye at Screening.\n4. Vision in the unoperated eye must be better or equal to vision in the study eye.\n5. Willing, committed, and able to return for ALL clinic visits and complete all study related procedures.\n6. Be medically suitable to undergo anesthesia, vitrectomy and subretinal injection in the opinion of the Investigator.\n7. Be medically suitable for immunosuppression therapy in accordance with the requirements of this protocol in the opinion of the Investigator.\n8. Able to read (or if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) and understand, and willing to sign the informed consent form (ICF)\n9. Willing to provide signed Informed Consent prior to any procedures being performed at Visit 1, Screening.\n10. Negative for HIV, HbsAg, HCV, TB\n11. The GA lesion must meet the following criteria as determined by the central reading center's assessment of Fundus Autofluorescence (FAF) imaging at screening:\n\n    1. Total GA area must be ≥ 1.25 and ≤ 17.5 mm2 (0.5 and 7 disk areas \\[DA\\] respectively)\n    2. The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.\n    3. At least one of the lesions has to be sub-foveal.\n\nExclusion Criteria:\n\n1. Have evidence of neovascular AMD in either eye by clinical examination, fluorescein angiography or optical coherence tomography.\n2. Have GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like Chloroquine maculopathy in either eye.\n3. Have any evidence of active or inactive choroidal neovascularization (CNV) due to other causes such as ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, uveitis, punctate inner choroidopathy, or multifocal choroiditis in the study eye.\n4. Axial myopia greater than -6 diopters or axial length more than 26 mm.\n5. Have a decrease in BCVA in the study eye due to causes other than GA (e.g., pigment abnormalities, dense sub foveal hard exudates, previous vitreoretinal surgery, retinal dystrophies, non-retinal conditions, visually significant cataract, macular ischemia, etc.).\n6. Have the presence of retinal pigment epithelial tears or rips involving the macula in the study eye at screening.\n7. Have a history or evidence of vitreous hemorrhage in the study eye.\n8. Have a history or clinical evidence of severe diabetic retinopathy, diabetic macular edema, retinal vein occlusion or any other vascular disease affecting the retina in the study eye.\n9. Have had a prior pars plana vitrectomy in the study eye.\n10. Have a history of retinal detachment or treatment or surgery for retinal detachment in the study eye.\n11. Have history of a macular hole in the study eye.\n12. Have had any other ocular surgery (except cataract) within 2 months or Yttrium Aluminum Garnet (YAG) laser capsulotomy in the study eye in the past 4 weeks.\n13. Have had a prior trabeculectomy or other filtration surgery in the study eye.\n14. History of any form of glaucoma in the study eye.\n15. Patients with ocular pathology, particularly that of retina (other than AMD).\n16. Have active intraocular inflammation or a history or evidence of uveitis in either eye.\n17. Have active ocular or periocular infection in either eye, or a history of any ocular or periocular infection within the 2 weeks prior to Visit 1, Screening in either eye.\n18. Have a history of scleromalacia in either eye.\n19. Have had previous therapeutic radiation in the study eye.\n20. Have a history of corneal transplant or corneal dystrophy.\n21. Have any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.\n22. Have a history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications.\n23. Have participated as a subject in any clinical study within 6 months prior to Day 0, Baseline.\n24. Have a known serious allergy to fluorescein sodium for injection in angiography, Povidone Iodine or any of the other medications required for anesthesia or the subretinal injection procedure.\n25. Be a female who is pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study at Screening and Baseline.\n26. Currently receiving aspirin, aspirin containing products and\u002For any other coagulation modifying drugs which cannot be discontinued 7 days prior to surgery.\n27. Have any systemic condition that would qualify the subject as being immunocompromised (e.g., severely uncontrolled diabetes, cancer).\n28. Patients with Optic Atrophy","100 Years",{"count":563,"type":19},54,[443,57],"The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).\n\nThe main questions it aims to answer are:\n\n* Safety and tolerability of the novel stem cell formulation\n* Potential efficacy of the novel stem cell formulation\n\nParticipants will receive a single subretinal injection in their study eye and followed up for safety.\n\nThis is an India only study and the product is developed indigenously.",[104,24,61,23,446],[130,23,568,569,570,571],"Visual Impairment","Subretinal injection","Stem cells","Retinal Pigment Epithelial Cells","2024-09-23",{"date":574,"type":35},"2024-09-24",{"date":576,"type":35},"2024-06-04",{"date":578,"type":19},"2030-12",{"name":580,"class":42},"Eyestem Research Pvt. Ltd.",3,{"id":583,"slug":584,"hasResults":11,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":215,"sex":16,"minAge":52,"maxAge":561,"enrollmentInfo":588,"targetDuration":4,"studyType":55,"phases":589,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":4},"100531334","vision-improvement-for-patients-with-age-related-macular-degeneration-100531334","NCT06198452","Vision Improvement for Patients With Age-Related Macular Degeneration","Inclusion Criteria:\n\nSubjects who meet all of the following criteria are candidates for this study:\n\n1. Male or Female\n2. Any race\n3. Patient is at least 50 years old.\n4. Patient has diagnosed end stage dry or wet age-related macular degeneration in one or both eyes, as verified by a complete ocular examination.\n5. Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s) to be treated.\n6. Patient has manifest refraction, spherical equivalent (MRSE) between -1.50 D to 1.50 D in eye(s) to be treated.\n7. Patient has moderate to severe vision impairment due to age-related macular degeneration with best spectacle-corrected distance visual acuity (CDVA) of 20\u002F80 or worse (decimal less than or equal to 0.25; logMAR ≥ 0.60).in the better eye.\n8. Patient has CDVA of 20\u002F400 or better (decimal greater than or equal to 0.05; logMAR ≤ 1.30) in the worse eye.\n9. Patient is not a contact lens (CL) wearer.\n10. Patient is willing and able to comply with all examinations.\n11. Patient must be competent to sign an informed consent form before study entry.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria are to be excluded from this study:\n\n1. Corneal disease or corneal disorder in either eye.\n2. Pathological retinal morphology in either eye that completely affects the entire 10° (3 mm diameter) of the retina centered on the foveola.\n3. Gonzalez-Markowitz chart Potential Visual Acuity (PVA) in the eye to be treated that is not improved by at least four lines compared to CDVA;\n4. Increased IOP (above 20 mm Hg), glaucoma or history of glaucoma;\n5. Previous corneal surgery in the eye to be treated; and\n6. Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or that may confound the outcome of the study.",{"count":354,"type":19},[101],"This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.",[24],"2024-08-30",{"date":594,"type":35},"2024-09-05",{"date":596,"type":19},"2025-01-01",{"date":598,"type":19},"2027-06-30",{"name":600,"class":42},"VIS, Inc.",{"id":602,"slug":603,"hasResults":11,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":215,"sex":16,"minAge":607,"maxAge":608,"enrollmentInfo":609,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":618,"locationsCount":206},"100521833","diagnostic-possibilities-in-ophthalmological-diseases-using-swept-source-optical-coherence-tomography-100521833","NCT06074731","Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography","Inclusion Criteria:\n\n* Age between 5 and 110 years\n* Ability to follow instructions during imaging procedure\n* Written Informed consent\n\nExclusion Criteria:\n\n* Dementia\n* Inability to follow instructions during imaging procedure\n* Patients who do not give informed consent","5 Years","110 Years",{"count":18,"type":19},"In this pilot study we want to investigate morphological features acquired by the novel image modality and gain information regarding disease pathomechanism, development and future possible influence on disease management for patients affected by those diseases.",[104,280,24],"2023-10-03",{"date":614,"type":35},"2023-10-10",{"date":616,"type":35},"2017-06-01",{"date":288,"type":19},{"name":619,"class":205},"Johannes Kepler University of Linz",{"id":621,"slug":622,"hasResults":11,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":627,"enrollmentInfo":628,"targetDuration":4,"studyType":55,"phases":629,"briefSummary":630,"conditions":631,"keywords":632,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":642,"locationsCount":206},"100473451","phase-1-safety-and-efficacy-of-autologous-transplantation-of-ipsc-rpe-in-the-treatment-of-macular-degeneration-100473451","NCT05445063","Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration","Safety and Efficacy of Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in the Treatment of Macular Degeneration","Inclusion Criteria:\n\n* Aged 50-75 years;\n* Clinical diagnosis is consistent with the definition of late dry AMD in the age-related eye disease study (AREDS), with one or more \\>250 um geographic atrophy in the fovea;\n* Clinical diagnosis is wet AMD, but no obvious efficacy after conventional treatment;\n* The BCVA of the target eye will be 0.05 to 0.3;\n* Voluntary as test subjects, informed consent, regular follow-up on time.\n\nExclusion Criteria:\n\n* One-eyed subjects;\n* Macular atrophy caused by other diseases in addition to AMD;\n* Suffer from retinitis pigmentosa, choroidal retinitis, central serous choroiditis, diabetic retinopathy, or other retinal vascular and degenerative diseases besides AMD;\n* Lens opacities (affecting the central vision), glaucoma, uveitis, retinal detachment, optic neuropathy, and other ocular histories;\n* Other intraocular surgery histories besides cataract surgery;\n* Combined with severe systemic diseases, such as heart failure, liver disease, renal insufficiency, cor pulmonale, COPD in the previous 12 months;\n* Combined with severe infectious diseases, such as HIV, HBV, HCV, syphilis, tuberculosis, etc;\n* Abnormal blood coagulation function or other laboratory tests;\n* If female and of childbearing potential, pregnant, breastfeeding, or planning to become pregnant through the study;\n* If male, refuse to use barrier and spermicide contraception during the study;\n* Malignant tumor and history of malignancy;\n* Any immune deficiency;\n* Allergy to tacrolimus or other macrolides;\n* Any immune deficiency;\n* Use glucocorticoids, immunosuppressive drugs, or antipsychotic drugs in the previous 3 months;\n* Use anticoagulant, or the platelet function is still not restored to normal after stopping antiplatelet drugs for 10 days;\n* A history of addiction to alcoholism or prohibited drugs;\n* Be participating in other intervention clinical trials or receiving other study medications;\n* Poor compliance, difficulty to complete the study, or refusal to informed consent;\n* Some other situations which might increase the risks of the subjects or interfere with clinical trials, such as mental disorders, cognitive dysfunction, etc.","75 Years",{"count":274,"type":19},[443],"This project intends to perform autologous transplantation of induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE). The clinical-grade RPE will be transplanted into subretinal space to treat refractory age-related macular degeneration. The efficacy and safety of RPE transplants to treat macular degeneration will be monitored and analyzed with results from EDTRS, BCVA, OCT, ERG, microperimetry, and fluorescein angiography, before and after the treatment.",[24],[633,634,121,635,29,421],"Retinal disease","Macular degeneration","RPE","2022-06-30",{"date":638,"type":35},"2022-07-06",{"date":640,"type":19},"2022-08",{"date":288,"type":19},{"name":643,"class":205},"Beijing Tongren Hospital"]